Adeno-associated virus (AAV) gene therapy has emerged as one of the most promising approaches in modern medicine, enabling researchers and developers to deliver functional genes directly to target tissues with increasing precision. Over the past decade, advances in vector engineering, manufacturing technologies, and translational science have accelerated the development of AAV therapeutics across rare diseases, neurology, ophthalmology, and beyond.
As the field evolves, success depends not only on scientific discovery, but also on the ability to scale manufacturing, maintain product quality, and navigate increasingly complex regulatory expectations. From early-stage AAV research through commercial readiness, developers are seeking integrated strategies that support efficient and clinical application.
An adeno-associated virus (AAV) is a small, non-pathogenic virus that belongs to the parvovirus family. It is commonly used as a vector in gene therapy because it can efficiently deliver genetic material into cells while causing minimal immune response.
In a typical AAV gene therapy approach, most of the virus's native genetic material is removed and replaced with a therapeutic gene cassette, while the viral capsid is retained to enable delivery into target cells. After administration, the AAV vector enters target cells and transports the therapeutic DNA, where the gene can be expressed to produce a missing, deficient, or therapeutic protein.
Importantly, AAV generally supports long-term gene expression in many tissues.
Today, several globally approved therapies leverage AAV technology, including treatments for spinal muscular atrophy (SMA), inherited retinal disorders, hemophilia, and other genetic diseases. These approvals have helped validate AAV gene therapy as a commercially viable therapeutic modality.
AAV is known for its many gene therapy applications due to its combination of safety, tissue specificity, and long-term therapeutic gene expression.
One of the primary reasons why AAV is used in gene therapy is its relatively low immunogenicity compared with some other viral delivery systems. While immune responses remain an important consideration during development, recombinant AAV (rAAV) vectors are generally well tolerated and have demonstrated strong clinical use across multiple therapeutic areas.
Another major advantage is the availability of naturally occurring and engineered AAV serotypes that can preferentially target specific tissues. The success and safety of gene therapy depend heavily on delivering the therapeutic gene to the right cells while minimizing exposure to non-target tissues. Different capsids exhibit varying tropisms for tissues such as skeletal muscle, liver, retina, central nervous system, and cardiac tissue, allowing developers to optimize delivery strategies based on therapeutic goals.
AAV vectors can also support long-lasting gene expression in non-dividing or slowly dividing cells. This characteristic is especially important for diseases where durable protein expression may reduce or eliminate the need for repeat dosing.
Because different gene therapy applications require different delivery strategies, vector selection is a critical development decision. For many in vivo programs, AAV has become a leading platform due to its tissue-targeting capabilities, established clinical track record, and potential to support long-term therapeutic benefit. This has helped drive continued investment in AAV research, process development, and manufacturing innovation across the industry.
AAV research began in the 1960s following the discovery of adeno-associated virus as a small, replication-deficient virus dependent on a helper virus to reproduce. Over time, researchers recognized its potential.
During the 1990s and early 2000s, advances in vector engineering and translational research helped establish rAAV vectors as viable tools for gene therapy applications. Many academic researchers contributed significantly to the understanding of AAV biology, tissue targeting, and clinical development strategies.
As clinical programs expanded, biotechnology companies and manufacturing organizations accelerated investment in scalable AAV production technologies, analytical characterization, and cGMP manufacturing infrastructure. These advances helped transition AAV technology from academic research into a clinically and commercially viable therapeutic platform.
Today, AAV therapeutics continue to advance across many indications.
History of rAAV from discovery to first in human use to first FDA approval to high yield processes.
Developing an AAV therapeutic requires coordinated work across vector engineering, analytical characterization, process development, translational research, and manufacturing strategy.
Programs typically begin with therapeutic target selection and transgene design, including promoter optimization and selection of regulatory elements that influence tissue specificity and expression levels. Developers then evaluate naturally occurring or engineered capsids based on biodistribution, tropism, and immunogenicity considerations. Preclinical studies use cell-based assays and animal models to gain insight into how the therapy will function in a clinical setting.
As candidates advance through preclinical development, analytical characterization becomes increasingly important. In fact, early manufacturing productions are often used in preclinical studies to help inform safety and efficacy of the therapy in parallel with process development and vector characterization. During this time, vector genome integrity, potency, purity, and stability are assessed to support regulatory submissions and process consistency.
Manufacturing strategy must also be considered early. Translation of the therapy into a clinical setting requires a clear plan for how the vector will be made and analyzed. As clinical studies advance and commercialization approaches, regulatory expectations of CMC rigor are increased. Factors such as plasmid design, suspension adaptation, purification efficiency, and scalability can significantly impact development timelines and commercial readiness. Many organizations now seek out platform-based manufacturing approaches that support smoother transitions from research through cGMP production.
AAV vectors are engineered delivery systems designed to transport therapeutic genes into target cells. During vector development, viral replication components are removed and replaced with a therapeutic transgene.
To improve targeting and performance further, researchers increasingly use engineered capsids and strategies designed to enhance biodistribution, reduce immune recognition, or improve transduction efficiency in difficult-to-target tissues.
As AAV therapeutics move toward broader indications and commercial scale, innovation is increasingly focused on scalability, manufacturing efficiency, and developing vectors with improved targeting, delivery, and clinical potential.
Synthetic capsid libraries, directed evolution, and computational modeling are helping researchers identify vectors with improved tissue specificity and delivery characteristics. Machine learning tools are also beginning to support capsid evaluation, variant screening, and vector optimization earlier in development, which are actively being reviewed by regulatory bodies.
At the same time, manufacturing strategy remains a critical consideration throughout development. As AAV programs advance, developers must evaluate how their manufacturing approach will support clinical timelines, scalability, process consistency, and future commercial needs.
The right path depends on the program. Some developers leverage platform technologies to accelerate development and streamline scale-up, while others require targeted process optimization or technology transfer strategies to align with specific product goals. By matching manufacturing solutions to program needs, teams can build a more efficient path from concept to clinic and beyond.
Forge’s FUEL™ platform combines proprietary technologies, including its novel pEMBR™ 2.0 Ad Helper, modified rep/cap plasmids, and HEK293 Ignition Cells™ to support higher-yield AAV manufacturing and scalable production from development through commercialization. The FUEL™ platform offers more efficient manufacturing so developers can get more doses from the same run for their patients.
AAV gene therapy offers several advantages that have contributed to its growth across the biopharmaceutical industry, though important scientific and manufacturing challenges remain.
A comparison of the four major systems for AAV production.
AAV manufacturing requires integrated, well-controlled processes that support product quality, scalability, and regulatory readiness across every stage of development.
Upstream production typically relies on transient transfection in suspension-adapted producer cell systems to generate recombinant AAV vectors. From early process development through clinical manufacturing, conditions are optimized to support consistent vector expression, productivity, and process robustness.
Downstream purification is then used to isolate and refine the vector product, removing impurities such as host cell proteins, residual DNA, and empty capsids. Analytical characterization is applied throughout the workflow to confirm product quality attributes, including identity, purity, potency, and consistency.
As programs progress into clinical and commercial stages, cGMP manufacturing infrastructure, validated analytical methods, and regulatory-aligned quality systems become increasingly important to support development milestones and regulatory expectations.
Forge has built its manufacturing capabilities specifically around AAV production, supporting programs from molecular development through cGMP manufacturing and fill-finish.
Forge’s dedicated AAV manufacturing facility, the Hearth, includes scalable bioreactor capacity and cGMP suites designed to support programs from early development through commercial manufacturing.
Regulatory agencies including the FDA and EMA require comprehensive data packages supporting the quality, safety, and clinical rationale of AAV gene therapy programs.
IND-enabling studies commonly include biodistribution assessments, toxicology evaluations, potency characterization, and dose-ranging studies. Developers must also demonstrate process consistency, impurity control, vector genome integrity, and analytical robustness throughout manufacturing.
Long-term safety monitoring remains important for gene therapy products as well.
As regulatory expectations continue to evolve, integrating manufacturing, analytical, and regulatory strategies early in development can help support more efficient clinical progression.
The future of AAV research will likely focus on improving delivery precision, overcoming immunity challenges, and expanding applications into larger patient populations and more complex diseases.
Capsid engineering remains a major area of innovation, particularly for CNS delivery and blood-brain barrier penetration. Researchers are also investigating strategies to improve redosing potential and reduce immune recognition.
At the same time, advances in manufacturing technology, analytics, and scalable production infrastructure will continue to shape the commercial future of AAV therapeutics.
As vector engineering and manufacturing capabilities evolve together, AAV technology is expected to remain a foundational platform across the next generation of genetic medicines.
Forge Biologics partners with gene therapy innovators to support their programs through every stage of development and manufacturing. From discovery support that helps establish a molecular foundation optimized for AAV manufacturing and rapid feasibility through research-grade production, to process development, cGMP manufacturing, and ultimately late-phase and commercial supply, we provide the expertise and capabilities needed for long-term success.
Ready to accelerate your AAV program from concept to clinical manufacturing? Connect with our team here.
Who developed AAV gene therapy initially?
AAV gene therapy was developed through decades of academic and industry research beginning after the discovery of adeno-associated virus in the 1960s. Researchers in structural virology and gene therapy, including Mavis Agbandje-McKenna and James M. Wilson, helped establish rAAV vectors as viable platforms for therapeutic gene delivery in the 1990s and early 2000s.
Are AAV-Based Gene Therapies FDA Approved?
Yes. Several FDA-approved therapies use AAV vectors for in vivo gene delivery, including treatments for spinal muscular atrophy, inherited retinal diseases, and hemophilia. These approvals have helped validate AAV as a leading platform in gene therapy development.
How does AAV target specific cells?
AAV vectors target specific tissues through differences in capsid structure and serotype tropism. Naturally occurring and engineered capsids can preferentially transduce tissues such as liver, muscle, retina, or the central nervous system, depending on the therapeutic application.
Can an AAV gene therapy be used more than once?
Redosing remains a challenge for many AAV therapies because patients may develop neutralizing antibodies after initial treatment. Researchers are actively investigating engineered capsids, immune modulation strategies, and alternative delivery approaches to improve future redosing potential.
What diseases can AAV therapies treat today?
AAV therapeutics are currently used or under investigation for a wide range of diseases, including spinal muscular atrophy (SMA), hemophilia, inherited retinal disorders, neuromuscular diseases, and certain central nervous system conditions. Research is also expanding into cardiology, metabolic disease, and oncology applications.
What makes AAV manufacturing so complex?
AAV manufacturing is a highly specialized process that requires balancing scientific, technical, and regulatory considerations to consistently produce safe, effective, and high-quality gene therapies. As programs advance from research through clinical and commercial stages, manufacturers must optimize processes for quality, scalability, and reliability while meeting stringent regulatory requirements.
Why is AAV commonly used in gene therapy?
AAV offers a favorable safety profile, the ability to support long-term gene expression in certain tissues, and broad range of tissue-targeting serotypes.